Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP: Benralizumab in Severe Eosinophilic Asthma
NCT06465485Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benralizumab in eosinophilic asthma (EA), sponsored by AstraZeneca. Started Feb 2024; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT06465485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465485.